• Scutellaria moniliorrhiza Komarov Labiatae is a

  2023-01-16

  

  Scutellaria moniliorrhiza Komarov (Labiatae) is a perennial herb and mainly distributed in Jilin province, China. In traditional Chinese medicine, the whole plants have been used to clear away heat-evil, expel superficial evils, eliminate stasis and reduce edema (He et al., 2012). In previous phytoc

• Gratifyingly compound also demonstrated improved

  2023-01-16

  

  Gratifyingly, compound also demonstrated improved physicochemical properties with significant improvement in aqueous solubility. Compound was sufficiently potent to determine its pharmacokinetic (PK) and pharmacodynamics (PD); data is summarized in . shows ADME characteristics for compound and

• The only psychostimulant treatment option in

  2023-01-16

  

  The only psychostimulant treatment option in Turkey is methylphenidate (Çetin et al., 2015). It is broken down by carboxylase enzyme (CES1) (Sun et al., 2004). From the point of pharmacokinetics, it may be suggested that CES1 gene polymorphisms may be the key responsible factors in patients resistan

• Adiponectin belongs to the CTRP

  2023-01-16

  

  Adiponectin belongs to the CTRP (C1q/TNF-related protein) superfamily. Except for adiponectin, 15 additional members have been identified (CTRP1-15) (Schaffler and Buechler, 2012). Of all the CTRPs, CTRP9 has the highest identity to adiponectin in globular domain (Wong et al., 2009). The structure o

• br Acknowledgements This work was supported

  2023-01-16

  

  Acknowledgements This work was supported by grants from the Program for Changjiang Scholars and Innovative Research Team in University (IRT_14R28), the National Basic Research Program of China (973) (Grant No.: 2013CB733602), the Major Research Plan of the National Natural Science Foundation of C

• During the year study period of men in the

  2023-01-16

  

  During the 4-year study period, 19.9% of men in the dutasteride group developed prostate cancer as compared to 25.1% in the placebo group, which represents an absolute risk MK2 inhibitor of 5.1% for men taking dutasteride (Pe weighed against the prospect of undesirable sexual side effects and decre

• DRiPs also contribute to formation of protein aggregates tha

  2023-01-16

  

  DRiPs also contribute to formation of protein PRT062607 Hydrochloride that result from dysregulation of proteostasis, during which the proteolytic machinery is unable to process and degrade defective proteins (Tyedmers et al., 2010). Aggregation of poly-ubiquitinated proteins has been observed in di

• In pancreatic islets we found an increase

  2023-01-16

  

  In pancreatic islets we found an increase in protein expression of leukocyte 12/15-LO that paralleled the metabolic decline characterized by severe hyperglycemia and reduced islet numbers. Similar increase in 12/15-LO expression by Western blot was found in the control mice, which have a normal meta

• As the experimental procedure used could

  2023-01-16

  

  As the experimental procedure used could reflect agonist-stimulation of both anterograde and retrograde APJ trafficking, as has been described for the δ-opioid peptide receptor (Zhang et al., 2006b, Zhang et al., 2006a), receptor internalization was more directly monitored by loading cell surface HA

• Glycosylphosphatidylinositol GPI cell wall anchor synthesis

  2023-01-16

  

  Glycosylphosphatidylinositol (GPI) Abiraterone mg anchor synthesis pathway is another promising antifungal target. Novel inhibitors of Gwt1 and Mcd4, two enzymes in the GPI anchor pathway were identified by the chemical-genomics-based screening platform CaFT (Candida albicans fitness test) [89]. Sc

• Recently the FDA approved the first

  2023-01-16

  

  Recently, the FDA approved the first blood-based test for the detection of EGFR mutations in non-small cell lung cancer patients (http://www.fda.gov) (Voelker, 2016). This allows detection of specific, recurrent mutations, which can help the selection of the patients that could benefit from Erlotini

• br Development of lorlatinib from crizotinib to a

  2023-01-14

  

  Development of lorlatinib from crizotinib (1) to a clinical candidate (6) Xalkori (1, PF-02341066, crizotinib), was the first-in-class ALK inhibitor approved by the Unites States Food and Drug Administration (FDA) in 2011 as a first-line treatment for ALK+- NSCLC patients. This section describes

• HsALDH enzyme has been purified for

  2023-01-14

  

  HsALDH enzyme has been purified for the first time in our laboratory from human saliva and has been kinetically characterized using different aromatic substrates [35]. Also, the effect of some common substances frequently encountered by the enzyme in the oral cavity (such as ethanol, hydrogen peroxi

• We found that several anticancer

  2023-01-13

  

  We found that several anticancer drugs inhibit 5-HT3 mini prep mg current in vitro. Several studies have suggested that 5-HT3 receptor antagonists have anti-mitogenic and apoptotic effects on colorectal and breast cancer cell lines (Ataee et al., 2010, Hejazi et al., 2015). Irinotecan is used frequ

• Several tertiary prevention studies are currently underway e

  2023-01-13

  

  Several tertiary prevention studies are currently underway examining the use of dutasteride for prostate cancer treatment: (1) during expectant management of prostate cancer, (2) after radical prostatectomy in men at high risk for relapse, and (3) in men with metastatic disease. The Reduction by Du

8326 records 396/556 page Previous Next First page 上5页 396397398399400 下5页 Last page